Advertisement
UK markets close in 6 hours 12 minutes
  • FTSE 100

    8,362.45
    +8.40 (+0.10%)
     
  • FTSE 250

    20,485.69
    -6.30 (-0.03%)
     
  • AIM

    781.54
    +1.71 (+0.22%)
     
  • GBP/EUR

    1.1626
    +0.0003 (+0.03%)
     
  • GBP/USD

    1.2472
    -0.0025 (-0.20%)
     
  • Bitcoin GBP

    49,064.72
    -867.99 (-1.74%)
     
  • CMC Crypto 200

    1,322.37
    +22.27 (+1.71%)
     
  • S&P 500

    5,187.67
    -0.03 (-0.00%)
     
  • DOW

    39,056.39
    +172.13 (+0.44%)
     
  • CRUDE OIL

    79.77
    +0.78 (+0.99%)
     
  • GOLD FUTURES

    2,317.50
    -4.80 (-0.21%)
     
  • NIKKEI 225

    38,073.98
    -128.39 (-0.34%)
     
  • HANG SENG

    18,537.81
    +223.95 (+1.22%)
     
  • DAX

    18,553.89
    +55.51 (+0.30%)
     
  • CAC 40

    8,125.81
    -5.60 (-0.07%)
     

MiMedx Group on the Street: Analyst Recommendations in January

MiMedx Group on the Street: Analyst Recommendations in January

MiMedx Group (MDXG) operates in the regenerative biomaterials segment. MiMedx is a leading global supplier of amniotic tissue products and has supplied over a million allografts in wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. Of the four analysts covering MiMedx Group in January 2018, three have given the stock a “buy” rating, and one analyst has given it a “strong buy” rating.